SCHEMBL796493

SCHEMBL796493

CCOc1ccc(C(=O)O)cn1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 1.00
L3MBTL1 Q9Y468 1/20 0.63
HCAR3 P49019 9/20 0.53
P4HTM Q9NXG6 3/20 0.52
P4HA1 P13674 2/20 0.52
MIF P14174 1/20 0.50
HCAR2 Q8TDS4 1/20 0.49
PLA2G4B P0C869 1/20 0.49
GABRP O00591 1/20 0.48
GABRD O14764 1/20 0.48
GABRA1 P14867 1/20 0.48
GABRB1 P18505 1/20 0.48
GABRG2 P18507 1/20 0.48
GABRB3 P28472 1/20 0.48
GABRA5 P31644 1/20 0.48
GABRA3 P34903 1/20 0.48
GABRA2 P47869 1/20 0.48
GABRB2 P47870 1/20 0.48
GABRA4 P48169 1/20 0.48
GABRE P78334 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2039201 0.86 MAPT (0.76) MAPTL3MBTL1PLA2G4B
SCHEMBL29788015 0.86 MAPT (0.76) MAPTL3MBTL1PLA2G4B
SCHEMBL10657063 0.86 MAPT (0.75) MAPTL3MBTL1HCAR3P4HTMP4HA1
SCHEMBL1092552 0.85 MAPT (0.74) MAPTL3MBTL1NNMTALDH1A1
SCHEMBL9446776 0.85 MAPT (0.73) MAPTL3MBTL1HCAR3P4HTMP4HA1
SCHEMBL14167872 0.85 MAPT (0.73) MAPTL3MBTL1HCAR3PLA2G4BGABRA5
SCHEMBL1461142 0.84 MAPT (0.73) MAPTL3MBTL1HCAR3PLA2G4BTSHR
SCHEMBL2817347 0.84 MAPT (0.72) MAPTL3MBTL1GABRA1TSHRNNMT
SCHEMBL27697095 0.84 MAPT (0.72) MAPTL3MBTL1NNMT
SCHEMBL10662876 0.83 MAPT (0.71) MAPTL3MBTL1HCAR3PLA2G4BTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12503477-B2 Colony stimulating factor-1 receptor (CSF-1R) inhibitors GENZYME CORPORATION 2025-12-23 US disclosed
US-20240217991-A1 COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS GENZYME CORPORATION (US) 2024-07-04 US disclosed
US-11697636-B2 Substituted benzamides HOFFMANN-LA ROCHE INC. (US) 2023-07-11 US disclosed
CN-113354635-B Pyrrolidine integrin regulator and application thereof 清药同创(北京)药物研发中心有限公司 2023-04-18 CN disclosed
US-20220396588-A1 COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS GENZYME CORPORATION (US) 2022-12-15 US disclosed
CN-107922396-B Colony stimulating factor-1 receptor (CSF-1R) inhibitors 建新公司 2022-08-05 CN disclosed
EP-3187490-B1 SUBSTITUTED BENZAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2022-04-06 EP disclosed
US-11274108-B2 Colony stimulating factor-1 receptor (CSF-1R) inhibitors GENZYME CORPORATION (US) 2022-03-15 US disclosed
CN-113354635-A Pyrrolidine integrin regulator and application thereof 清药同创(北京)药物研发中心有限公司 2021-09-07 CN disclosed
EP-3186224-B1 SUBSTITUTED AZETIDINE DERIVATIVES AS TAAR LIGANDS HOFFMANN LA ROCHE (CH) 2021-04-21 EP disclosed
EP-2158198-A2 NOVEL N- (8HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N- (5- HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN AstraZeneca AB (SE) 2010-03-03 EP disclosed
WO-2009145899-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORPORATION (US) 2009-12-03 WO disclosed
US-20090142297-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORPORATION 2009-06-04 US disclosed
WO-2008130320-A2 NOVEL N- (8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N- (5- HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN ASTRAZENECA AB (SE) 2008-10-30 WO disclosed
US-20070203136-A1 TRIAZOLOPYRIDAZINES AS KINASE MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-08-30 US disclosed
US-5216170-A Promoters of livestock; treatment of obesity BAYER AKTIENGESELLSCHAFT (DE) 1993-06-01 US disclosed
US-5028617-A Heteroarylethanol-pyridylalkylamines for controlling animal growth BAYER AKTIENGESELLSCHAFT (DE) 1991-07-02 US disclosed
EP-0379928-A2 Aryl- and heteroarylethanol-pyridylalkylamines, process for their preparation and their use as performance stimulators by animals and as anti-adipositas agent BAYER AG (DE) 1990-08-01 EP disclosed
EP-0258430-A1 NEMATIC LIQUID CRYSTAL PHASES MERCK PATENT GmbH (DE) 1988-03-09 EP disclosed
WO-1987005316-A1 NEMATIC LIQUID CRYSTAL PHASES MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 1987-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11274108-B2 Colony stimulating factor-1 receptor (CSF-1R) inhibitors CSF1R, CSF3R, IL1RN MAPT 2666/4885L3MBTL1 4566/4885HCAR3 596/4885
US-20070203136-A1 TRIAZOLOPYRIDAZINES AS KINASE MODULATORS RET, MET, ABL1 MAPT 3784/4885L3MBTL1 1318/4885HCAR3 1513/4885
US-20240217991-A1 COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS CSF1R, CSF3R, IL1RN MAPT 2666/4885L3MBTL1 4566/4885HCAR3 596/4885
US-20090142297-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CYP3A5, CYP3A7, CYP3A4 MAPT 1498/4885L3MBTL1 3940/4885HCAR3 632/4885
US-20220396588-A1 COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS CSF1R, CSF3R, IL1RN MAPT 2666/4885L3MBTL1 4566/4885HCAR3 596/4885
US-12503477-B2 Colony stimulating factor-1 receptor (CSF-1R) inhibitors CSF1R, CSF3R, IL1RN MAPT 1811/4885L3MBTL1 4691/4885HCAR3 910/4885
US-11697636-B2 Substituted benzamides TAAR1, TAAR5, NPY1R MAPT 387/4885L3MBTL1 3261/4885HCAR3 287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.